Translated by google from ...
http://www.flutrackers.com/forum/showthread.php?t=117200
(Quebec) M?dicago will export its technology to manufacture influenza vaccines to France.
The biopharmaceutical Quebec announced yesterday the conclusion of a partnership agreement for the production of vaccines with Genopole, a biotechnoparc located in Evry, or twenty kilometers southeast of Paris.
"The money to build the plant and make it work and will of Genopole we on our side, we will ensure a transfer of our technology," said Sun President and CEO of Medicago, Andy Sheldon.
Rather than using conventional methods on the eggs to produce vaccines against seasonal influenza and pandemic - the processes that often stretch over a period of six months - M?dicago manufactures its vaccines from virus DNA sequence and different varieties of plants. This allows to create a vaccine within a month and at reduced costs.
Obviously, Andy Sheldon is happy to see that Genopole - which brings together 69 companies and twenty research laboratories focusing on genetics and biotechnology? has chosen to rely on technology developed by Medicago. "It'sa great recognition of the work we do here," he said stressing that the techno-economic viability of the project had been a feasibility study.
One of the problems related to the fight against influenza is the distribution of plants producing vaccines throughout the world. Corners of the world are less well equipped than others. "Our strategy is to implement our technology around the world so that we can respond quickly to the demand for vaccines at the time the order situation," Sheldon says, stressing that it was the whole Medicago first foray abroad.
"This new facility will strengthen the leadership of our biopark innovation and bioproduction offering unique manufacturing capacity to France and Europe," said the CEO of Genopole, Pierre Tambourin.
M?dicago recently received the green light by Health Canada to begin testing its vaccine candidate against H5N1 avian influenza in humans. Clinical trials of phase one should begin at the end of the month.
In this regard, the biotech has completed preclinical studies in ferrets have shown that very low doses of a pandemic vaccine, made against the Indonesian strain of avian influenza H5N1, had obtained a 100% protection against exposure fatal to the very virulent strain Vietnam. "
A safety study was also conducted on rats and showed that the vaccine was well tolerated and had caused no significant side effects.
In the case of influenza A (H1N1), M?dicago continued testing on animals. Produced in only 14 days after obtaining the DNA sequence of the virus, the vaccine candidate is already showing positive results after the first tests in mice.
In addition, M?dicago has recently undertaken an expansion of its production plant located in the Quebec Metro High Tech Park. This is an investment of close to one million dollars.
At the Toronto Stock Exchange under the M?dicago (TSX Venture: MDG) was yesterday, 33 cents.
http://www.flutrackers.com/forum/showthread.php?t=117200
(Quebec) M?dicago will export its technology to manufacture influenza vaccines to France.
The biopharmaceutical Quebec announced yesterday the conclusion of a partnership agreement for the production of vaccines with Genopole, a biotechnoparc located in Evry, or twenty kilometers southeast of Paris.
"The money to build the plant and make it work and will of Genopole we on our side, we will ensure a transfer of our technology," said Sun President and CEO of Medicago, Andy Sheldon.
Rather than using conventional methods on the eggs to produce vaccines against seasonal influenza and pandemic - the processes that often stretch over a period of six months - M?dicago manufactures its vaccines from virus DNA sequence and different varieties of plants. This allows to create a vaccine within a month and at reduced costs.
Obviously, Andy Sheldon is happy to see that Genopole - which brings together 69 companies and twenty research laboratories focusing on genetics and biotechnology? has chosen to rely on technology developed by Medicago. "It'sa great recognition of the work we do here," he said stressing that the techno-economic viability of the project had been a feasibility study.
One of the problems related to the fight against influenza is the distribution of plants producing vaccines throughout the world. Corners of the world are less well equipped than others. "Our strategy is to implement our technology around the world so that we can respond quickly to the demand for vaccines at the time the order situation," Sheldon says, stressing that it was the whole Medicago first foray abroad.
"This new facility will strengthen the leadership of our biopark innovation and bioproduction offering unique manufacturing capacity to France and Europe," said the CEO of Genopole, Pierre Tambourin.
M?dicago recently received the green light by Health Canada to begin testing its vaccine candidate against H5N1 avian influenza in humans. Clinical trials of phase one should begin at the end of the month.
In this regard, the biotech has completed preclinical studies in ferrets have shown that very low doses of a pandemic vaccine, made against the Indonesian strain of avian influenza H5N1, had obtained a 100% protection against exposure fatal to the very virulent strain Vietnam. "
A safety study was also conducted on rats and showed that the vaccine was well tolerated and had caused no significant side effects.
In the case of influenza A (H1N1), M?dicago continued testing on animals. Produced in only 14 days after obtaining the DNA sequence of the virus, the vaccine candidate is already showing positive results after the first tests in mice.
In addition, M?dicago has recently undertaken an expansion of its production plant located in the Quebec Metro High Tech Park. This is an investment of close to one million dollars.
At the Toronto Stock Exchange under the M?dicago (TSX Venture: MDG) was yesterday, 33 cents.